NCT00468143View on ClinicalTrials.gov

A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall

PHASE4CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

Adderall ® Immediate Release

Adderall Immediate release (IR) was provided as treatment for three weeks (at 15, 30 or 45 mg TID). The medication was optimized for titration.

DRUG

Adderall XR ®

Adderall Extended Release (XR) was provided as treatment for three weeks at (15, 30, or 45 mg QD). The medication was optimized for titration.

Trial Locations (1)

10010

VANYHHS, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT00468143 - A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall | Biotech Hunter | Biotech Hunter